Patients in Oklahoma are paying up to 6x more for medications at hospital-owned facilities compared to independent clinics. HB 2048 would only make this worse by expanding 340B without accountability. We urge Governor Kevin Stitt to veto HB 2048 to protect Oklahoma patients. #OKleg

UnitedHealth is under DOJ investigation for potential Medicare fraud tied to its Advantage plans. With a 50% stock drop and CEO shakeup, scrutiny grows. Transparency is critical. #DOJInvestigation wsj.com/us-news/united…

Cancer patients deserve access to local care, not a system that drives oncology providers out of business. #HB2048 in #OKLeg expands 340B abuse that benefits large hospital systems, not patients. The Oklahoma State Senate should vote no on the veto override and protect rural oncology access.

In a new @TigerlilyCares blog, a Chicago-based oncologist discusses how #340B is failing to support patients or lower costs while also disrupting the cancer care system. Read more on the need for transparency in the program: bit.ly/Tigerlily-CHOP

PBMs should put patients first, not profits. Patients deserve lower drug prices and greater access to affordable care. Support #HB264 transparency. Kirk Talbot Adam Bass Sen. Regina Barrow, President Pro Tem Royce Duplessis Rick Edmonds Senator Franklin Foil Brach Myers Rep. Alan Seabaugh Robert Allain III #LaLeg

#MCEDAct is the first healthcare bill to gain majority cosponsorship in both the House & Senate! U.S. Senator Bill Cassidy, M.D. is on board, but we need John Kennedy to cosponsor. Let’s pass this bill NOW! Speaker Mike Johnson Steve Scalise Leader John Thune Senator Mike Crapo fightcancer.org/releases/legis…

The 340B program cost drugmakers $70B in 2023—translating to $14B in lost tax revenue. Reform is needed to ensure transparency, protect patients, and safeguard taxpayer dollars. #340B #DrugPricing washingtontimes.com/news/2025/may/…

PBMs are suing to block state laws limiting their control over pharmacies. As states push back, the fight for transparency, access, and fair pricing is heating up. #PBMs #DrugPricing #HealthcareReform axios.com/2025/06/03/pbm…

Entities in the 340B program charge 7–20% more than non-340B peers—costing employers & families $36B/year. It’s time for reform. 📄 340breform.org/wp-content/upl… #340B

Louisiana sues CVS for misusing patient data, underpaying independents & inflating drug costs. A bold move demanding transparency & fairness in pharmacy benefit management. #PBMs #Healthcare apnews.com/article/louisi…

PBMs were meant to lower drug costs—but now they profit off rebates, spread pricing & patient steering. It’s time to reform the system, not just punish bad actors. #PBMreform #DrugPricing forbes.com/sites/gebai/20…

PBMs continue to profit while patients pay the price. Our President Kathy Oubre advocates for transparency and reform to protect access to cancer care. #DrugPricing #PBMs #OncologyCare #340B linkedin.com/posts/american…

Who decides if a cancer drug is “worth it”? Former FDA reviewer says patient voices are missing from the equation—and it’s time they’re heard. #PatientVoice #CancerCare oncologynewscentral.com/oncology/who-d…

Fraud, antitrust & public nuisance claims are proving effective in holding PBMs accountable for high drug costs & harmful practices. Legal pressure is mounting. #PBMs #DrugPricing #HealthcareJustice news.bloomberglaw.com/employee-benef…

The OBBB Act could cut 300+ hospitals from 340B by changing eligibility rules—impacting vulnerable patients. Reform should ensure transparency, accountability, and patient-focused savings. pricepoints.health/p/obbb-340b?ut…

A judge blocked Arkansas' PBM reform law—protecting corporate PBMs, not patients. 3 PBMs control 84% of the market. That’s not choice—it’s a monopoly. #PBMReform #PharmacyAccess katv.com/news/local/ark…

States are stepping up on PBM reform—tackling rising drug costs, transparency, and unfair pharmacy practices. Arkansas and Texas are leading. Will others follow? #PBMReform #DrugPricing #Healthcare pharmacytimes.com/view/op-ed-sta…

Senate drops PBM reform from Trump’s budget—analysts say delinking PBM pay from drug prices could’ve saved $95B/yr. The move leaves big questions on lowering costs & boosting transparency. #PBMReform pharmavoice.com/news/pbm-refor…

PBMs decide which meds patients can access & at what cost. A bipartisan push in Congress aims to rein in these middlemen & ensure transparency. Patients, not profits, must come first. #PBMReform wgal.com/article/what-a…